# Zentalis (ZNTL) Stock Price, News & Analysis
Canonical URL: https://biopharmsignal.com/company/ZNTL
## Company Profile
- Ticker: ZNTL
- Exchange: NASDAQ
- Sector: Small Molecule Drugs
- Location: United States
- Tags: Small Molecule Drugs, Oncology, Hematology
## Stock Data
- Close: 4.11 USD
- Market cap: 281186074.6 USD
- Last updated: 2026-08-11
## Business Overview
### Cell-Cycle Oncology Company
Zentalis Pharmaceuticals develops azenosertib, an oral inhibitor of WEE1, a regulator of DNA-damage checkpoints and cell-cycle progression.
### Cyclin E1-Positive Ovarian Cancer
The lead program targets platinum-resistant ovarian cancers with Cyclin E1 expression, where replication stress may create heightened dependence on WEE1.
### DENALI and ASPENOVA
DENALI is the registration-intended Phase 2 monotherapy study, while ASPENOVA is a Phase 3 confirmatory trial intended to support full approval and ex-U.S. registrations.
## Why The Stock Is Moving

As of Aug 11, 2026, ZNTL closed down 0.96% at $4.11. No new same-company headline was identified in the current news window.

## Future Catalysts

- Topline results from the Phase 2 DENALI study are expected by year-end 2026 and may support an Accelerated Approval pathway, subject to the data and FDA feedback.

## Recent News
- 2026-08-06 20:05 EST — [Zentalis Pharmaceuticals Reports Second Quarter 2026 Financial Results and Business Updates](https://biopharmsignal.com/news/ZNTL/zentalis-pharmaceuticals-reports-second-quarter-2026-financial-results-and-busin-c4940e1e) — Source: Zentalis
- 2026-07-17 20:15 EST — [Zentalis Pharmaceuticals to Present at the European Society for Medical Oncology (ESMO) Congress 2026](https://biopharmsignal.com/news/ZNTL/zentalis-pharmaceuticals-to-present-at-the-european-society-for-medical-oncology-7b982012) — Source: Zentalis
- 2026-06-01 21:00 EST — [Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/ZNTL/zentalis-pharmaceuticals-announces-inducement-grants-under-nasdaq-listing-rule-5-1f326240) — Source: Zentalis
- 2026-05-27 20:05 EST — [Zentalis Strengthens Commercial Leadership with Appointments of Shannon Campbell to Board of Directors and Sarah Kelly as SVP of Commercial Strategy](https://biopharmsignal.com/news/ZNTL/zentalis-strengthens-commercial-leadership-with-appointments-of-shannon-campbell-34c7acfb) — Source: Zentalis
- 2026-05-21 21:39 EST — [Zentalis Pharmaceuticals to Present Phase 1b MUIR Trial Data Showing Encouraging Clinical Activity and Manageable Safety Profile of Azenosertib Plus Paclitaxel in Platinum-Resistant Ovarian Cancer at ASCO 2026](https://biopharmsignal.com/news/ZNTL/zentalis-pharmaceuticals-to-present-phase-1b-muir-trial-data-showing-encouraging-6d0f0eb0) — Source: Zentalis